1.
|
Ferlay J, Bray F, Pisani P and Parkin DM:
GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence
Worldwide. IARC CancerBase No. 5, Version 2.0. IARC Press; Lyon:
2004
|
2.
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
3.
|
Motzer RJ, Dror Michaelson M, Redman BG,
et al: Activity of SU11248, a multitargeted inhibitor of vascular
endothelial growth factor receptor and platelet-derived growth
factor receptor, in patients with metastatic renal cell carcinoma.
J Clin Oncol. 24:16–24. 2006. View Article : Google Scholar
|
4.
|
Motzer RJ, Rini BI, Bukowski RM, et al:
Sunitinib in patients with metastatic renal cell carcinoma. JAMA.
295:2516–2524. 2006. View Article : Google Scholar : PubMed/NCBI
|
5.
|
Motzer RJ, Hutson TE, Tomczak P, et al:
Sunitinib versus inter-feron alpha in metastatic renal-cell
carcinoma. N Engl J Med. 356:115–124. 2007. View Article : Google Scholar : PubMed/NCBI
|
6.
|
Escudier B, Eisen T, Stadler WM, et al:
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J
Med. 356:125–134. 2007. View Article : Google Scholar : PubMed/NCBI
|
7.
|
Szcylik C, Demkow T, Staehler M, et al:
Randomized phase II trial of first-line treatment with sorafenib
versus interferon in patients with advanced renal cell carcinoma:
final results. J Clin Oncol. 25:50252007.
|
8.
|
Aso Y, Tazaki H, Umeda T and Marumo K: A
phase II study of S-6820 (recombinant interleukin-2) on renal cell
carcinoma (in Japanese). Biotherapy. 3:999–1007. 1989.
|
9.
|
Aso Y, Homma Y, Tazaki H, et al: A phase
II trial of S-6820 (recombinant interleukin-2) on renal cell
carcinoma refractory to interferon (in Japanese). Hinyokigeka.
8:75–86. 1995.
|
10.
|
Hayashi T, Miyagawa Y, Tsujimura A,
Nonomura N, Minami M and Okuyama A: A case of renal cell carcinoma
with multiple lung metastases refractory to interferon-α showing
complete remission by interleukin-2 monotherapy. Int J Urol.
13:805–808. 2006.PubMed/NCBI
|
11.
|
Kobayashi M, Ikeda H, Nukui A, et al:
Clinical outcome and prognostic survival factors in patients with
advanced renal cell carcinoma treated with very low-dose
interleukin-2, interferon-α and tegafur-uracil: a
single-institution experience. Int J Clin Oncol. 13:257–262.
2008.
|
12.
|
Wirth MP: Immunotherapy for metastatic
renal cell carcinoma. Urol Clin North Am. 20:283–295.
1993.PubMed/NCBI
|
13.
|
Horoszewicz JS and Murphy GP: An
assessment of the current use of human interferons in therapy of
urological cancers. J Urol. 142:1173–1180. 1989.PubMed/NCBI
|
14.
|
Bukowski RM: Natural history and therapy
of metastatic renal cell carcinoma: the role of interleukin-2.
Cancer. 80:1198–1220. 1997. View Article : Google Scholar : PubMed/NCBI
|
15.
|
Motzer RJ and Russo P: Systemic therapy
for renal cell carcinoma. J Urol. 163:408–417. 2000. View Article : Google Scholar : PubMed/NCBI
|
16.
|
Klapper JA, Downey SG, Smith FO, et al:
High-dose interleukin-2 for the treatment of metastatic renal cell
carcinoma: a retrospective analysis of response and survival in
patients treated in the Surgery Branch at the National Cancer
Institute between 1986 and 2006. Cancer. 113:293–301. 2008.
|
17.
|
Belldegrun AS, Klatte T, Shuch B, et al:
Cancer-specific survival outcomes among patients treated during the
cytokine era of kidney cancer (1989–2005): a benchmark for emerging
targeted cancer therapies. Cancer. 113:2457–2463. 2008.PubMed/NCBI
|
18.
|
Akaza H, Tsukamoto T, Onishi T, Miki T,
Kinouchi T and Naito S: A low-dose combination therapy of
interleukin-2 and interferon-α is effective for lung metastasis of
renal cell carcinoma: a multi-center open study. Int J Clin Oncol.
11:434–440. 2006.
|
19.
|
Akaza H, Kawai K, Tsukamoto T, et al:
Successful outcomes using combination therapy of interleukin-2 and
interferon-α for renal cell carcinoma patients with lung
metastasis. Jpn J Clin Oncol. 40:684–689. 2010.
|
20.
|
WHO Handbook for Reporting Results of
Cancer Treatment: WHO Offset Publication No. 48. World Health
Organization; Geneva: 1979
|
21.
|
Japanese Urological Association and
Japanese Society of Pathology: Response criteria for urological
cancer treatment. Jpn J Urol. 83:447–472. 1992.
|
22.
|
Golub TR, Slonim DK, Tamayo P, et al:
Molecular classification of cancer: class discovery and class
prediction by gene expression monitoring. Science. 286:531–537.
1999. View Article : Google Scholar : PubMed/NCBI
|